HROW
Harrow Health Inc
30.60$
+0.9%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +6.1% | -4.9% | +41.5% | +0.6% | +35.7% | -28.4% | +33.3% | +12.4% | +24.4% | -50.4% | +59.9% | – | |
| – | +12.3% | -6.6% | +18.8% | -4.2% | +17.6% | +9.8% | +4.5% | +9.1% | +4.3% | -7.1% | +18.3% | – | |
| – | +3.5% | -4.1% | +51.5% | +2.3% | +41.5% | -38.7% | +47.1% | +13.5% | +31.0% | -61.7% | +86.2% | – | |
| – | +134.8% | -35.6% | +42.1% | -25.5% | +109.2% | -36.4% | -5.2% | +15.9% | -1.5% | +80.1% | +36.9% | – | |
| – | +24.6% | +9.9% | +10.4% | +5.7% | +3.4% | +16.5% | -18.0% | +7.9% | +20.8% | -0.2% | +23.3% | – | |
| – | +33.3% | +3.5% | +12.6% | +3.0% | +10.8% | +9.4% | -17.1% | +8.5% | +18.9% | +5.5% | +24.9% | – | |
| – | -379.5% | – | – | -13.7% | +876.5% | -187.1% | – | +29.3% | +63.0% | -191.8% | – | – | |
| – | -10.9% | +5.7% | +1.0% | +1.0% | +15.4% | +2.7% | -2.1% | -5.8% | -14.1% | +6.0% | +13.9% | – | |
| – | – | – | – | – | – | -383.9% | – | -79.6% | +919.3% | -365.2% | – | – | |
| – | -134.8% | – | -79.1% | -96.9% | -2,670.0% | – | – | – | – | -99.3% | – | – | |
| – | – | – | – | – | – | -362.4% | – | -79.6% | +549.6% | -516.6% | – | – | |
| – | -130.1% | – | – | +71.0% | +309.9% | -138.1% | – | -27.2% | +75.2% | -181.0% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.